Takeda
650 East Kendall Street
Cambridge
MA
02421
United States
Website: https://www.takeda.com/
Email: info@takeda.com
About Takeda
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions.
For more information, visit https://www.takeda.com.
Stock Symbol: TAK
Science is the foundation for everything we do at Takeda. We connect to our 240- year history and our strong values through our pursuit of life-transforming science where we embrace a culture of collaboration, pursue modalities based on validated targets, evaluate real-world impact and generate data that may enable accelerated development and regulatory pathways.
1524 articles about Takeda
-
Late Breaking Data Presented at the American Diabetes Association 71st Annual Scientific Sessions Evaluate the Safety and Tolerability of TAK-875, Takeda Pharmaceutical Co. Ltd.'s Investigational Compound for the Treatment of Type 2 Diabetes
6/28/2011
-
Takeda Pharmaceutical Co. Ltd.'s Actos, GlaxoSmithKline's Avandia Raise Risk of Eye Disease
6/27/2011
-
Drug Maker Redwood Bioscience Inc. Raises Funds from Takeda Pharmaceutical Co. Ltd.
6/27/2011
-
European Medicines Evaluation Agency Delays Verdict on Takeda Pharmaceutical Co. Ltd. Diabetes Drug to July
6/24/2011
-
FDA Says Heavy Use of Takeda Pharmaceutical Co. Ltd.'s Actos May Be Tied to Bladder Cancer
6/16/2011
-
Germany Joins France In Suspending Takeda Pharmaceutical Co. Ltd.'s Actos; Japan Does Not Plan to Recall Drug
6/10/2011
-
France Suspends Takeda Pharmaceutical Co. Ltd.'s Actos and Competact Over Bladder Cancer Concerns
6/9/2011
-
Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Announce the Submission of a New Drug Application for Peginesatide for the Treatment of Anemia Associated with Chronic Renal Failure in Patients on Dialysis
5/31/2011
-
Takeda Pharmaceutical Co. Ltd.'s Data from Phase 3 Studies of Investigational Fixed-Dose Combination of Azilsartan Medoxomil Plus Chlorthalidone Presented at the American Society of Hypertension Annual Scientific Meeting
5/23/2011
-
Takeda Pharmaceutical Co. Ltd. Nails Nycomed Buyout for $13.7 Billion, Skin Unit to Spin Off
5/19/2011
-
Is Takeda Pharmaceutical Co. Ltd. Finally Set to Buy Nycomed for $12 Billion? - Deal to be Formally Announced Today
5/18/2011
-
Takeda Pharmaceutical Co. Ltd. Taking Steps for 10-Fold Increase in China Revenues
5/17/2011
-
More Signs Takeda Pharmaceutical Co. Ltd.'s Diabetes Drug, Actos Linked to Bladder Cancer
5/17/2011
-
Breckenridge Pharmaceutical, Inc. and Synthon Pharmaceuticals Announces Settlement of Actos(R) (Pioglitazone Hydrochloride) Patent Litigation With Takeda Pharmaceutical Co. Ltd.
5/16/2011
-
Takeda Pharmaceutical Co. Ltd. Denies Reaching Agreement to Buy Nycomed
5/13/2011
-
Takeda Pharmaceuticals Bets on Fate Therapeutics
5/10/2011
-
Takeda Pharmaceutical Co. Ltd. and Pronova BioPharma Announce Top-line Results of the Pivotal Phase 3 Clinical Trial of TAK-085 in Japan for Treatment of Hypertriglyceridemia
5/10/2011
-
Affymax, Inc. and Takeda Pharmaceutical Co. Ltd. Report Additional Phase 3 Clinical Trial Data for Peginesatide in Dialysis Patients at the National Kidney Foundation Spring Clinical Meetings
4/28/2011
-
Takeda Pharmaceuticals North America, Inc.'s EDARBI (azilsartan medoxomil), Now Available in U.S. Pharmacies for Patients With Hypertension
4/15/2011
-
Takeda Cambridge in Second Deal to Expand Use of Dimerix Bioscience’s GPCR-HIT Platform
4/13/2011